UPC · Universe Pharmaceuticals INC
$5.03
-0.33 (-6.16%)
At close · Aug 25
Market Cap
$3.56M
Shares
663,915
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.03
Open$5.16
Day$5.03–5.36
52W close$2.25–12.18
Avg vol 30d1.4M
Short int35K · 5.3% float · 1.0d
Short vol13%
DataMar 2025–Aug 2026
Raw chart and full-history price indicators begin at the captured split on Mar 24, 2025; bars on opposite sides are not compared.
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+34%
above
Price vs 50-day avg
+3%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
28%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+58%
trailing
6-month return
+91%
trailing
YTD return
+32%
this year
Relative strength
+79%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.33% of float · ▲ +454.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — mid 3-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
−22%
Y/Y
Gross margin
35%
expanding
EPS growth
+99%
Y/Y
Free cash flow
$-5.3B
Balance sheet
$7.1B
net debt
Quant / Vol
risk profile
Volatility
360%
annualized · 1-yr
Max drawdown
−76%
past year
ATR
15.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+34%
Bullish
Price vs 50-day avg
+3%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
28%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.33% of float · ▲ +454.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $5 · 28%
Range high $12
vs 200-day avg +34%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UPC
this stock
Universe Pharmaceuticals INC
|
$3.56M | +32.0% | -22.4% | — | 5.3% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.25B | +17.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.94B | +3.4% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.98B | +0.7% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
4
- % held
- 5.6%
- Net QoQ
- +37.5K sh
- Top holder
- HRT FINANCIAL LP
Held
Float
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Mar 24, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UPC | -3.8% | +57.7% | +90.5% | +59.2% | +32.0% |
| SPY | -0.2% | +3.4% | +11.8% | +2.5% | +12.3% |
| vs SPY | -3.6% | +54.3% | +78.7% | +56.7% | +19.7% |
Key facts
CIK
1809616
CUSIP
G9442G138
13F (30d)
4 filings
4 filers